The litigation centers on claims that PROCEPT BioRobotics misled the market by utilizing a discount program that encouraged customers to order handpieces far beyond actual clinical demand. According to the complaint, this practice created an unsustainable glut of over 10,000 excess units in the field. Plaintiffs argue these actions allowed the company to inflate its financial reports and issue revenue guidance for 2025 that lacked a factual foundation.
Investors Eye Lead Role in PROCEPT BioRobotics Securities Fraud Suit
Investors who lost over $100,000 in PROCEPT BioRobotics stock between February 2024 and February 2026 have until September 22 to apply as lead plaintiffs in a pending securities class action. The lawsuit alleges the company artificially inflated sales figures through undisclosed bulk-order incentive programs, leading to significant financial losses for shareholders.
Rosen Law Firm, which filed the action, is currently soliciting participants for the class. Under the proposed timeline, the court will appoint a lead plaintiff by September 22, 2026. While the firm is actively recruiting, investors retain the right to select their own counsel or remain absent class members without taking immediate action. No class has been certified at this stage, meaning investors are not yet represented unless they formally retain an attorney.
Comments (0)
No comments yet. Be the first!